تحميل...
Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
INTRODUCTION: Maintenance of drug efficacy and safety over the long term is important to investigate for progressive conditions like type 2 diabetes mellitus (T2DM). This study aimed to evaluate whether efficacy of dapagliflozin added to glimepiride observed at 24 weeks was maintained at 48 weeks, a...
محفوظ في:
المؤلفون الرئيسيون: | , , , , , |
---|---|
التنسيق: | Artigo |
اللغة: | Inglês |
منشور في: |
Springer Healthcare
2014
|
الموضوعات: | |
الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4065289/ https://ncbi.nlm.nih.gov/pubmed/24920277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0072-0 |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|